Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Tomei

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|June 14, 2021
Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic TechnologiesCristian Scatena, Daniela Murtas, Sara Tomei
Cancer Immunology, Immunotherapy : CII|May 12, 2012
Reflections upon human cancer immune responsiveness to T cell-based therapyEna Wang, Sara Tomei, Francesco M Marincola
Cell Stem Cell|May 6, 2022
Death by differentiation: CD4<sup>+</sup> T cells kick out suspicious stem cellsSara Tomei, Cindy Audiger, Shalin H Naik
Nature Immunology|July 13, 2023
tDCs - a distinct subset with dual functional and developmental rolesCindy Audiger, Sara Tomei, Shalin H Naik
Blood|May 6, 2026
The Evolution of Haematopoietic Models Through a Clonal LensSara Tomei, Tom S Weber, Shalin H Naik
Microrna (Shariqah, United Arab Emirates)|July 3, 2019
Updates on the Current Technologies for microRNA ProfilingRebecca Mathew, Valentina Mattei, Muna Al Hashmi, et al.
Annals of the New York Academy of Sciences|May 9, 2013
Common pathways to tumor rejectionEna Wang, Davide Bedognetti, Sara Tomei, et al.
Cancers|April 30, 2021
Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAsSara Tomei, Ola Ibnaof, Shilpa Ravindran, et al.
Microrna (Shariqah, United Arab Emirates)|April 13, 2021
The Salivary miRNome: A Promising Biomarker of DiseaseSara Tomei, Harshitha Shobha Manjunath, Selvasankar Murugesan, et al.
Expert Opinion on Biological Therapy|March 15, 2014
Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanomaSara Tomei, Ena Wang, Lucia Gemma Delogu, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|June 14, 2021
Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic TechnologiesCristian Scatena, Daniela Murtas, Sara Tomei
Cancer Immunology, Immunotherapy : CII|May 12, 2012
Reflections upon human cancer immune responsiveness to T cell-based therapyEna Wang, Sara Tomei, Francesco M Marincola
Cell Stem Cell|May 6, 2022
Death by differentiation: CD4<sup>+</sup> T cells kick out suspicious stem cellsSara Tomei, Cindy Audiger, Shalin H Naik
Nature Immunology|July 13, 2023
tDCs - a distinct subset with dual functional and developmental rolesCindy Audiger, Sara Tomei, Shalin H Naik
Blood|May 6, 2026
The Evolution of Haematopoietic Models Through a Clonal LensSara Tomei, Tom S Weber, Shalin H Naik
Microrna (Shariqah, United Arab Emirates)|July 3, 2019
Updates on the Current Technologies for microRNA ProfilingRebecca Mathew, Valentina Mattei, Muna Al Hashmi, et al.
Annals of the New York Academy of Sciences|May 9, 2013
Common pathways to tumor rejectionEna Wang, Davide Bedognetti, Sara Tomei, et al.
Cancers|April 30, 2021
Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAsSara Tomei, Ola Ibnaof, Shilpa Ravindran, et al.
Microrna (Shariqah, United Arab Emirates)|April 13, 2021
The Salivary miRNome: A Promising Biomarker of DiseaseSara Tomei, Harshitha Shobha Manjunath, Selvasankar Murugesan, et al.
Expert Opinion on Biological Therapy|March 15, 2014
Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanomaSara Tomei, Ena Wang, Lucia Gemma Delogu, et al.
Pageof 8